Key facts
- It has raised $16.1M; the latest was Early Stage VC ($14.5M) in Mar 2026.
- Notable investors include SND Ventures Group, Zhengxuan Investment, GSR United Capital, Suzhou Nanhui Zhongcheng Entrepreneurship Investment, Insigma Technology — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for LeadMuta
- ·The full record, as it builds
Funding rounds
No funding rounds for LeadMuta are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LeadMuta
Developer of innovative drugs designed to accelerate small-molecule research from target identification through preclinical optimization. The company offers integrated capabilities spanning computational chemistry workflows of small molecules and to create a new drug research and development pipeline based on artificial intelligence, computational chemistry, medicinal chemistry, and other disciplines, enabling patients to have new drugs sooner.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- leadmuta.com/
- Ownership
- Privately Held (backing)
LeadMuta doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LeadMuta shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LeadMuta in its N-PORT filings yet. We sweep new filings monthly.